MUNICH, Germany – April 10, 2018 – At Analytica 2018
Bruker today announces the launch of the new INVENIO™ Fourier Transform Infrared (FT-IR) research spectrometer. The INVENIO is the successor to the renowned VERTEX 70 FT-IR for advanced R&D applications.
The novel INVENIO combines many innovations with proven Vertex 70 technologies, such as unique FM technology for simultaneous mid and far IR spectroscopy. The new MultiTectTM technology allows for control of up to five internal detectors, covering the spectral range from far infrared to Vis/UV. A DigiTectTM detector slot enables additional flexibility for even more detectors. The smart INVENIO beam path further improves optical throughput and spectroscopic sensitivity.
In addition to performance and flexibility, a major goal of the INVENIO is to simplify the research user's experience. An integrated touch panel enables intuitive configuration set-ups and workflows for R&D applications, and the system can also be switched to notebook operation. The TransitTM channel allows for easy transmission measurements, without removing experiments from the sample compartment.
The INVENIO is an intelligent spectrometer with many exciting features that set it apart from other research FT-IRs. These include electronically coded beam windows with magnetic mount, an automated internal attenuator wheel and an 8-position validation wheel for standards and customer-specific filters. The unique Bruker RocksolidTM interferometer and FM technology for simultaneous mid and far IR complete the INVENIO feature set.
About Bruker Corporation
For more than 55 years, Bruker has enabled scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy, nanoanalysis and industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research, clinical microbiology and molecular pathology research.
For more information on INVENIO, please visit: www.bruker.com/invenio
|Media Contact||Investor Contact|
T: +49 (7243) 504-2652
Head of Investor Relations
T: +1 (978) 663-3660, ext. 1479